Letrozole is a non-steroidal aromatase inhibitor. It inhibits the aromatase enzyme by competitive binding to the harem of cytochrome P450 aromatase, resulting in reduced estrogen biosynthesis in all tissues where it is present. GALDAR® (letrozole) is used for different therapeutic applications including: a) adjunctive treatment of hormone receptor-positive early breast cancer in postmenopausal women; b) adjuvant continuation therapy of hormone-dependent early breast cancer in postmenopausal women who have previously received standard adjuvant tamoxifen therapy for 5 years; c) first-line treatment of advanced hormone-dependent breast cancer in women; d) advanced breast cancer in women in a natural or artificially caused postmenopausal state, after relapse or progression of the disease, who have previously been treated with antiestrogens. Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer. GALDAR® is available in 2.5 mg tablets and in packs of 30 tablets.
For further information: